Treace Medical Concepts, Inc. (NASDAQ:TMCI) just released its second-quarter report and things are looking bullish. Revenues beat expectations coming in atUS$45m, ahead of estimates by 3.3%. Statutory losses were somewhat smaller thanthe analysts expected, coming in at US$0.24 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Following last week's earnings report, Treace Medical Concepts' five analysts are forecasting 2026 revenues to be US$207.5m, approximately in line with the last 12 months. The loss per share is expected to ameliorate slightly, reducing to US$0.85. Before this latest report, the consensus had been expecting revenues of US$206.3m and US$0.90 per share in losses. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrade to loss per share forecasts for this year.

These new estimates led to the consensus price target rising 18% to US$5.50, with lower forecast losses suggesting things could be looking up for Treace Medical Concepts. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Treace Medical Concepts, with the most bullish analyst valuing it at US$7.00 and the most bearish at US$4.50 per share. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Treace Medical Concepts' revenue growth is expected to slow, with the forecast 2.1% annualised growth rate until the end of 2026 being well below the historical 18% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 7.6% per year. Factoring in the forecast slowdown in growth, it seems obvious that Treace Medical Concepts is also expected to grow slower than other industry participants.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Treace Medical Concepts going out to 2028, and you can see them free on our platform here.

Even so, be aware that Treace Medical Concepts is showing 2 warning signs in our investment analysis , you should know about...

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.